Zhejiang Medicine's Chief Medical Officer Resigns!

MaticHoleFiller · 2026-04-01T19:48:54+00:00

Zhejiang Medicine announced that Chief Scientific Officer Sheng Zeqi has resigned due to personal reasons but will serve as a Senior Scientific Advisor. She was responsible for new drug research and development at the subsidiary GENSUN, and her responsibilities have been taken over by Zhejiang Medicine's Chairman and core technical personnel. Currently, the company has integrated a large-molecule antibody technology platform.

MaticHoleFiller

2026-04-01 19:48:54

Abstract generation in progress

(Source: Pharmacy Circle Headlines)

On the evening of March 27, Zegen Pharmaceutical released an announcement. The company’s core technical personnel, Ms. JACKIE ZEGI SHENG (Sheng Zeqi), has, due to personal reasons, recently applied to resign from her positions as the company’s Chief Scientific Officer and as a position held at its subsidiary, Gensun Biopharma Inc.

After her resignation, Ms. Sheng Zeqi will no longer serve as Zegen Pharmaceutical’s Chief Scientific Officer, nor as GEN SUN’s director and Chief Executive Officer. Zegen Pharmaceutical will appoint Ms. Sheng Zeqi as the company’s Senior Scientific Advisor to ensure the related work is carried out smoothly and that a successful transition is completed.

During Ms. Sheng Zeqi’s tenure, she was mainly responsible for the early R&D and management of GENSUN’s new drug projects, the company’s subsidiary, and also served as the company’s Chief Scientific Officer. Currently, GENSUN’s R&D projects, R&D activities, and related business have been taken over by Zegen Pharmaceutical. The related work will be jointly undertaken by the company’s Chairman, General Manager, core technical personnel Mr. ZELIN SHENG (Sheng Zelin), and also jointly by the Director, Deputy General Manager, and core technical personnel Mr. Lü Binhua.

Zegen Pharmaceutical and its subsidiary GENSUN teams are collaborating on the R&D of large-molecule antibody new drugs. GENSUN is mainly responsible for early exploratory research such as molecular design of antibody therapeutics and part of the in vitro experimental screening for new molecules. Meanwhile, the vast majority of antibody R&D work is implemented by Zegen Pharmaceutical, including antibody molecular synthesis and screening, all antibody CMC work, preclinical pharmacology and toxicology research, clinical research, and so on. As of now, Zegen Pharmaceutical has completed the integration and enhancement of the large-molecule antibody technology platform, and the subsidiary’s R&D projects, R&D activities, and related business have been taken over by the company.

A massive amount of information and precise analysis—only in the Sina Finance App

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes